2 not yet recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow Relapse: new trials by email Literature Review of Relapse trials Research Report on Relapse
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia Daratumumab - Aplastic Anemia, Refractory | Phase 1 / Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 37 | 2025-12-10 | 2025-12-17 |
| Allogeneic Immunotherapy of Hematological Malignancies Using Regulatory T-cell Selective Depletion T-reg depleted DLI - Hematological Malignancies, Regulatory T Cell Depletion | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 27 | 2024-03-01 | 2024-02-14 |
Recurrence (2) · Anemia, Aplastic (1) · Hematologic Neoplasms (1)
Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Anemia (1) · Bone Marrow Diseases (1) · Bone Marrow Failure Disorders (1) · Neoplasms (1) · Neoplasms by Site (1)
daratumumab (1)
Assistance Publique - Hôpitaux de Paris (1) · Institute of Hematology & Blood Diseases Hospital, China (1)
China (1)